Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will determine the safety and feasibility of using a β-blocker (in this case
carvedilol) in the treatment of pediatric patients with Left Heart Failure (LHF) in children
with Pulmonary Arterial Hypertension (PAH). Carvedilol affects the nervous system, the same
system that is highly activated in response to stress in patients with PAH. Each patient is
administered a dosage of carvedilol, according to their weight. This dosage is increased
incrementally over the span of the study, if the patient responds well to the drug. The study
will determine whether the potential adverse side effects of carvedilol outweigh the possible
positive results in reducing LHF. The hypothesis of this study predicts that carvedilol will
have positive effects in treating LHF, similar to their use in treatment of Right Heart
Failure (RHF). This is a single-centered pilot study. Each patient will be studied for
approximately 31 weeks.